MOLRECORD
PAPER SUMMARY PAPER Metabolic and the GLP-1 class

GLP-1 drugs recruit hunger neurons to sustain fat loss, Yale study finds

A mechanism that cuts against the assumption that AgRP neurons only oppose weight loss.

Published 5 Oct 2026 Event 10 Aug 2026 Sources 1 EVIDENCE · PRECLINICAL MECHANISMMODEL · ANIMALPUBLISHED · AUG 2026
INSTITUTION
Yale
MODEL
Animal
REPORTED
10 Aug 2026
STATUS
Published

What was done

The study examined agouti-related peptide (AgRP) neurons, a hypothalamic population that drives feeding, during treatment with GLP-1 receptor agonists. The prevailing view had been that the drugs work partly by suppressing AgRP activity. [1]

What was found

According to the university's account, GLP-1 therapy instead recruited AgRP neurons in a way that helped sustain fat loss, challenging the assumption that these neurons act only to oppose weight reduction. [1]

Limits

This summary is from the university news release. The journal citation, model details and effect sizes will be added from the paper itself. [1]

Funding

To be added from the paper's disclosure statement.

SOURCES

  1. Yale News. New study may change how we think about GLP-1s. 10 Aug 2026. Institutional news. https://news.yale.edu/2026/08/10/new-study-may-change-how-we-think-about-glp-1s

CHANGELOG · 5 Oct 2026 FIRST PUBLISHED · CORRECTIONS ARE ADDED HERE, NEVER HIDDEN